Ontuxizumab
Ontuxizumab
Ontuxizumab (pronunciation: on-tux-i-zu-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets a specific protein called endosialin, which is often overexpressed in many types of cancer.
Etymology
The name "Ontuxizumab" is derived from the International Nonproprietary Names (INN), where "on-" refers to neoplastic (tumor), "-tu-" refers to the target (in this case, endosialin), "-xi-" denotes that it is a chimeric antibody, and "-mab" is the suffix for monoclonal antibodies.
Mechanism of Action
Ontuxizumab works by binding to the endosialin protein on the surface of cancer cells. This binding inhibits the growth and spread of cancer cells. The drug is usually given by intravenous infusion.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Endosialin: A protein that is often overexpressed in many types of cancer.
- Intravenous infusion: A method of delivering medication or other substances directly into a vein.
See Also
External links
- Medical encyclopedia article on Ontuxizumab
- Wikipedia's article - Ontuxizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski